BridgeBio Pharma secured $1 billion through preferred equity investment led by Sixth Street and HealthCare Royalty to support upcoming drug launches and strengthen its financial position. The funding comes as BridgeBio prepares to launch three potential blockbuster therapies in the next year, including treatments for LGMD2I/R9, ADH1, and achondroplasia. This capital boost enables BridgeBio to allocate resources efficiently and advance its mission to develop medicines for genetic conditions. The investment terms include a 7% dividend and conversion prices at significant premiums to current stock prices, reflecting strong investor confidence.
BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrated early and sustained kidney-protective effects in clinical trials. The drug caused a reversible dip in kidney filtration rate and reduc...
BridgeBio Pharma is rated a Buy due to the commercial launch of Attruby and its promising late-stage pipeline focused on rare genetic diseases. The company's valuation exceeds $14 billion, supported by four potential blockbuster drugs expected by 203...
BridgeBio Pharma announced that the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia demonstrated significant improvements in height velocity, body proportionality, and arm span compared to placebo. These results, published...
